PASO has been a teriffic stock for us and many investors - up over 300% since our initial recommendation. The stock has been strong because of the strong product offerings put forth by the company. The most important of these was the Electronic Medical Record (EMR) product that is geared for the smaller physician practices. As we have written in previous reports, larger physician’s offices and hospitals have a multitude of choices relative to the implementation of EMR. The smaller practices, however how far fewer options due mainly to cost and support issues. PASO has devised a product that is directly targeted at these smaller practices.
The company has also recently entered the home healthcare market through its exclusive partnership with a Swedish company that markets and innovative electronic pen system that allows the home healthcare worker to simply write in an ordinary manner and have this handwriting directly entered as text into computer systems. The home healthcare market is valued in excess of $55 billion per year within the United States alone. When we view the opportunity for PASO relative to small physician offices and home healthcare, it is very clear why investors have become excited about the companies opportunities.
The management team recently announced its intention to move to the OTC market and off of the pink sheets. An important component of this movement is the completion of a full financial review by an auditing firm. It now appears this review is virtually completed. This will allow the company to file the necessary paperwork with market makers and regulators in order to move back to OTC trading.
We were very positive on Patient Access Solutions (PASO) and we will be closely monitoring customer acquisition activities over the coming weeks. Joe Noel
